Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Peritoneal dialysis solution with dextrose as osmotic agent; removes solutes and water across peritoneal membrane via diffusion and ultrafiltration.
Intraperitoneal administration of dextrose creates an osmotic gradient that promotes ultrafiltration and removal of uremic toxins and excess fluid across the peritoneal membrane, while electrolytes in the solution correct imbalances.
Intraperitoneal administration: 2 L per exchange, typically 4 exchanges daily (continuous ambulatory peritoneal dialysis). Dextrose 4.25% solution used for ultrafiltration. Dose adjusted based on body size and fluid status.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, via continuous ambulatory peritoneal dialysis (CAPD).
None Documented
None Documented
Not applicable as a drug; dextrose is rapidly metabolized; plasma half-life of glucose ~1.5-2 hours; continuous reabsorption in dialysis prevents accumulation.
Not applicable (combination product); dextrose follows glucose kinetics (~1.5–2 h); electrolytes have no half-life.
Peritoneal dialysis; effectively removed via peritoneal membrane during dialysis exchanges; systemic absorption of dextrose minimal; elimination primarily through dialysate outflow; renal excretion negligible in anuria.
Primarily renal; glucose is reabsorbed or metabolized; electrolytes follow renal handling. Not applicable as a drug; dialysate components are removed via peritoneal dialysis effluent.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution